无合并症的真实慢性乙型肝炎免疫耐受期患者不建议抗病毒治疗

全敏; 邢卉春

doi:10.3969/j.issn.1001-5256.2021.06.011

无合并症的真实慢性乙型肝炎免疫耐受期患者不建议抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2021.06.011

全敏,
邢卉春^,

首都医科大学附属北京地坛医院肝病三科，北京 100015

基金项目:

北京市医院管理中心扬帆计划 (xmlx201837);

十三五艾滋病和病毒性肝炎等重大传染病防治 (2018ZX10302206－003-006);

北京市医院管理中心消化内科学科协同发展中心项目 (XXT26);

首都卫生发展科研专项 (首发2020-1-2171)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：全敏、邢卉春负责构思和文献检索; 全敏负责起草全文和修改; 邢卉春负责文章修改和审校。

详细信息

通信作者:
邢卉春，hchxing@sohu.com

中图分类号: R512.62
计量
- 文章访问数: 459
- HTML全文浏览量: 66
- PDF下载量: 78
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-23
- 录用日期: 2021-05-15
- 出版日期: 2021-06-20

Antiviral therapy is not recommended in immune-tolerant phase chronic hepatitis B patients without complications

Min QUAN,
Huichun XING^,

Third Department of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

摘要

- 乙型肝炎病毒 /
- 乙型肝炎, 慢性 /
- 免疫耐受 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Immune Tolerance /
- Therapeutics

HTML全文

参考文献(12)

[1]	FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011.
[2]	ATTAR BM. CON: All patients with immune-tolerated hepatitis B virus do not need to be treated[J]. Clin Liver Dis (Hoboken), 2020, 15(1): 25-30. DOI: 10.1002/cld.893.
[3]	CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044.
[4]	WU ZX, CHEN FS, ZHOU XL, et al. Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 832-835. DOI: 10.1097/MEG.0000000000001345.
[5]	FELD JJ, TERRAULT NA, LIN HS, et al. Entecavir and peginterferon alfa-2a in adults with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(6): 2338-2348. DOI: 10.1002/hep.30417.
[6]	HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724.
[7]	LEE HW, KIM EH, LEE J, et al. Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase[J]. Clin Transl Gastroenterol, 2020, 11(3): e00140. DOI: 10.14309/ctg.0000000000000140.
[8]	CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
[9]	KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904.
[10]	ZHANG N, ZHAO YY, OU WN, et al. Analysis on the liver histology of 229 chronic hepatitis B patients with normal or slightly elevated alanine aminotransferase level[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2014, 8(1): 14-17. DOI: 10.3877/cma.j.issn.1674-1358.2014.01.004. 张娜, 赵莹莹, 欧蔚妮, 等. 肝功能正常或轻度异常的慢性HBV感染者肝组织病理改变分析[J/CD]. 中华实验和临床感染病杂志(电子版), 2014, 8(1): 14-17. DOI: 10.3877/cma.j.issn.1674-1358.2014.01.004.
[11]	LIAW YF, BRUNETTO MR, HADZIYANNIS S. The natural history of chronic HBV infection and geographical differences[J]. Antivir Ther, 2010, 15(Suppl 3): 25-33. DOI: 10.3851/IMP1621.
[12]	ANDREANI T, SERFATY L, MOHAND D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome[J]. Clin Gastroenterol Hepatol, 2007, 5(5): 636-641. DOI: 10.1016/j.cgh.2007.01.005.